A disease that affects fewer than 200,000 people in the United States is considered a rare disease. There are currently over 10,000 rare diseases, and more than 20 million Americans suffer from a rare disease. Approximately 75% of rare diseases affect children, and approximately 30% of these children die before age 5. Most rare diseases in children are caused by a specific gene mutation. Today’s advanced genetic diagnostic technology is effective at diagnosing and identifying most rare diseases. Some genetic diseases are easily identified by physical abnormalities, whereas the presence of most rare diseases is only evident when a child fails to thrive or develop normally. When this happens, diagnosing the rare disease is still relatively quick and accurate. However, this is where the system breaks down. Less than 10% of rare diseases have FDA-approved treatments. Pharmaceutical research into finding treatments for rare diseases focuses on the specific genetic pathway affected. Also, pharmaceutical research requires that new drugs or procedures have patent protection to justify the cost of development. This is legitimate research and science. However, pharmaceutical treatment is not the only viable approach and is not necessarily the best approach to restoring health in someone with a rare disease.
In children, the debilitating effects of a rare disease are caused by the rare disease preventing or blocking some critical growth or developmental process. In human biochemistry, most biochemical systems have alternative pathways to achieve the same function. However, these alternative pathways often cannot fully compensate for the defective component, resulting in overall system failures. In certain circumstances, using more advanced biochemical engineering, function of the overall system can be restored to full or near full capacity.
Each rare disease is unique. Improved health has been observed in children with peroxisomal diseases such as rhizomelic chondrodysplasia punctata (RCDP), leukodystrophies, mitochondrial defects, Duchenne’s muscular dystrophy, Rett’s syndrome, and others.
We do not treat MS – we support the body’s health in those living with it. Our approach focuses on identifying and restoring the underlying biological systems that MS affects, particularly those involved in myelination, inflammation, and cellular resilience.
Rather than managing the disease label, we work to restore the functions MS disrupts: movement, cognition, communication, and quality of life. This is not passive care – it’s a biologically guided, client-empowered process of recovery.
The Biochemistry of MS
From a biochemical perspective, MS is a breakdown of membrane systems - especially the white matter myelin that insulates neurons and the lipid pathways that maintain it. This breakdown includes:
• Plasmalogen depletion, especially omega-9 plasmalogens critical to white matter integrity
• Impaired mitochondrial and peroxisomal function, reducing cellular energy and repair capacity
• Inflammatory and oxidative stress cascades, triggered by membrane instability
• Neurological disconnection, due to compromised neurotransmission and axonal signaling
MS isn’t caused by one single problem it’s a cascade of dysfunction, and rebuilding begins with restoring what’s missing at the molecular level.
Symptoms are real – but they’re not the starting point. Restoration starts with the core systems that make function possible.
How we treat health in MS
We dont' treat the disease. We treat the health affected by it. That means:
- Rebuilding membrane structure with lipid-based nutrients
- Supporting energy production and antioxidant capacity
- Measuring functional outcomes (not just imaging)
- Guiding each person based on their own biochemistry
